Targeted metagenomic primer sets and kits for detecting multiple respiratory pathogens
By designing 59 pairs of specific primers and a high-throughput sequencing platform, the problem of detecting multiple respiratory pathogens in existing technologies has been solved, enabling rapid and accurate multiplex PCR amplification and pathogen identification. It is suitable for high-sensitivity and high-specificity detection of a variety of respiratory pathogens.
Patent Information
- Application Number
- CN202411302869.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-19
AI Technical Summary
Existing technologies struggle to simultaneously detect multiple respiratory pathogens, including bacteria, fungi, mycoplasma, and viruses, resulting in poor amplified library quality and hindering the achievement of highly sensitive and high-resolution detection.
We designed 59 pairs of specific primers to perform multiplex PCR amplification of 27 respiratory pathogens, and combined them with a high-throughput sequencing platform to achieve accurate identification of respiratory pathogens.
It enables rapid and accurate detection of a variety of respiratory pathogens, covering common and rare pathogenic microorganisms. It is easy to operate, fast and accurate, with high sensitivity and specificity, and is suitable for the entire process of testing a small number of clinical samples.
Smart Images

Figure CN118813840B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biological detection, and relates to a targeted metagenomic primer set and a kit for detecting multiple respiratory pathogens. Background Art
[0002] Diseases caused by acute respiratory infections include acute upper respiratory tract infection, acute tracheobronchitis, bronchopneumonia, bronchiectasis, etc. The clinical manifestations of these diseases are not consistent. There are many kinds of pathogens that cause respiratory infections, such as viruses, bacteria, mycoplasma, chlamydia, Legionella and other microorganisms. One pathogen can cause multiple clinical manifestations, and the same clinical manifestation can be caused by multiple pathogens. In practice, it is often difficult to treat according to clinical manifestations, which can easily cause some patients to have long-term fever, even worsening of the disease, and abuse of antibiotics. Therefore, rapid detection of pathogens of respiratory infections is of great significance for timely clinical diagnosis and epidemic reporting.
[0003] Targeted next-generation sequencing (tNGS) provides a possibility for the detection of respiratory pathogens. It uses a large number of primers / probes targeting specific gene sequences to perform super-multiplex PCR amplification / probe capture on the nucleic acids extracted from the test samples to obtain a large number of target nucleic acid fragments, and then performs high-throughput sequencing on these target nucleic acid fragments. The resulting sequences are then subjected to bioinformatics analysis, thereby achieving highly sensitive and high-resolution identification of nucleic acids in the test samples.
[0004] Based on the technical principle of tNGS, CN117187443A provides a targeted detection kit for detecting multiple pathogens at the same time, and its preparation method and application, which can simultaneously detect influenza A virus, influenza B virus, syncytial virus and new coronavirus. CN115948607A provides a method for simultaneously detecting multiple pathogen genes, which realizes the detection of multiple bacteria and fungi in bloodstream infection. The existing technologies, including the above patents, are mostly for one type of pathogen inspection, and cannot be used for simultaneous detection of bacteria, fungi, mycoplasma, and viruses. When detecting multiple pathogen genes, hundreds of thousands of primers for specific amplification of pathogenic microorganisms are included in the multiple PCR primer pool, but in the actual sample to be tested, there are usually only a small number of microorganisms or even none. In this case, only a few pairs of primers among hundreds of thousands of primers will actually amplify, and the remaining large number of primers will form a large number of dimers or non-specific amplifications due to the lack of target DNA template consumption, which will lead to poor quality of the amplified library. Summary of the invention
[0005] The present invention realizes the simultaneous detection of bacteria, fungi, mycoplasma and viruses, and solves the technical problem that the prior art can only detect a single type of pathogen and is difficult to detect multiple types of pathogens.
[0006] The present invention relates to the following technical solutions:
[0007] In one aspect, the present invention relates to a primer set consisting of the following primer pairs:
[0008] Primer pairs for Staphylococcus aureus, such as the primer pair shown in SEQ ID NO: 1 and SEQ ID NO: 2, the primer pair shown in SEQ ID NO: 3 and SEQ ID NO: 4, and the primer pair shown in SEQ ID NO: 5 and SEQ ID NO: 6;
[0009] A primer pair for Mycobacterium tuberculosis complex, such as the primer pair shown in SEQ ID NO: 7 and SEQ ID NO: 8, and the primer pair shown in SEQ ID NO: 9 and SEQ ID NO: 10;
[0010] A primer pair for Streptococcus pneumoniae, such as the primer pair shown in SEQ ID NO: 11 and SEQ ID NO: 12, the primer pair shown in SEQ ID NO: 13 and SEQ ID NO: 14, and the primer pair shown in SEQ ID NO: 15 and SEQ ID NO: 16;
[0011] Primer pairs for Acinetobacter baumannii, such as the primer pair shown in SEQ ID NO: 17 and SEQ ID NO: 18, the primer pair shown in SEQ ID NO: 19 and SEQ ID NO: 20, and the primer pair shown in SEQ ID NO: 21 and SEQ ID NO: 22;
[0012] A primer pair for Escherichia coli, such as the primer pair shown in SEQ ID NO: 23 and SEQ ID NO: 24, the primer pair shown in SEQ ID NO: 25 and SEQ ID NO: 26, and the primer pair shown in SEQ ID NO: 27 and SEQ ID NO: 28;
[0013] A primer pair for Haemophilus influenzae, such as the primer pair shown in SEQ ID NO: 29 and SEQ ID NO: 30, the primer pair shown in SEQ ID NO: 31 and SEQ ID NO: 32, and the primer pair shown in SEQ ID NO: 33 and SEQ ID NO: 34;
[0014] A primer pair for Klebsiella pneumoniae, such as the primer pair shown in SEQ ID NO: 35 and SEQ ID NO: 36, the primer pair shown in SEQ ID NO: 37 and SEQ ID NO: 38, and the primer pair shown in SEQ ID NO: 39 and SEQ ID NO: 40;
[0015] A primer pair for Pseudomonas aeruginosa, such as the primer pair shown in SEQ ID NO: 41 and SEQ ID NO: 42, the primer pair shown in SEQ ID NO: 43 and SEQ ID NO: 44, and the primer pair shown in SEQ ID NO: 45 and SEQ ID NO: 46;
[0016] A primer pair for Stenotrophomonas maltophilia, such as the primer pair shown in SEQ ID NO: 47 and SEQ ID NO: 48, the primer pair shown in SEQ ID NO: 49 and SEQ ID NO: 50, and the primer pair shown in SEQ ID NO: 51 and SEQ ID NO: 52;
[0017] A primer pair for Mycoplasma pneumoniae, such as the primer pair shown in SEQ ID NO: 53 and SEQ ID NO: 54, the primer pair shown in SEQ ID NO: 55 and SEQ ID NO: 56, and the primer pair shown in SEQ ID NO: 57 and SEQ ID NO: 58;
[0018] A primer pair for human adenovirus A, such as the primer pair shown in SEQ ID NO: 59 and SEQ ID NO: 60, and the primer pair shown in SEQ ID NO: 61 and SEQ ID NO: 62;
[0019] A primer pair for human adenovirus B, such as the primer pair shown in SEQ ID NO: 63 and SEQ ID NO: 64, and the primer pair shown in SEQ ID NO: 65 and SEQ ID NO: 66;
[0020] A primer pair for human adenovirus C, such as the primer pair shown in SEQ ID NO: 67 and SEQ ID NO: 68, and the primer pair shown in SEQ ID NO: 69 and SEQ ID NO: 70;
[0021] A primer pair for human adenovirus D, such as the primer pair shown in SEQ ID NO: 71 and SEQ ID NO: 72, and the primer pair shown in SEQ ID NO: 73 and SEQ ID NO: 74;
[0022] A primer pair for human adenovirus E, such as the primer pair shown in SEQ ID NO: 75 and SEQ ID NO: 76, and the primer pair shown in SEQ ID NO: 77 and SEQ ID NO: 78;
[0023] A primer pair for human adenovirus F, such as the primer pair shown in SEQ ID NO: 79 and SEQ ID NO: 80, and the primer pair shown in SEQ ID NO: 81 and SEQ ID NO: 82;
[0024] A primer pair for human adenovirus G, such as the primer pair shown in SEQ ID NO: 83 and SEQ ID NO: 84, and the primer pair shown in SEQ ID NO: 85 and SEQ ID NO: 86;
[0025] A primer pair for rhinovirus, such as the primer pair shown in SEQ ID NO: 87 and SEQ ID NO: 88;
[0026] A primer pair for the novel coronavirus, such as the primer pair shown in SEQ ID NO: 89 and SEQ ID NO: 90;
[0027] A primer pair for influenza A virus, such as the primer pair shown in SEQ ID NO: 91 and SEQ ID NO: 92;
[0028] A primer pair for influenza B virus, such as the primer pair shown in SEQ ID NO: 93 and SEQ ID NO: 94;
[0029] A primer pair for respiratory syncytial virus, such as the primer pair shown in SEQ ID NO: 95 and SEQ ID NO: 96;
[0030] A primer pair for Aspergillus flavus, such as the primer pair shown in SEQ ID NO: 97 and SEQ ID NO: 98, and the primer pair shown in SEQ ID NO: 99 and SEQ ID NO: 100;
[0031] A primer pair for Aspergillus fumigatus, such as the primer pair shown in SEQ ID NO: 101 and SEQ ID NO: 102, and the primer pair shown in SEQ ID NO: 103 and SEQ ID NO: 104;
[0032] A primer pair for Aspergillus niger, such as the primer pair shown in SEQ ID NO: 105 and SEQ ID NO: 106, and the primer pair shown in SEQ ID NO: 107 and SEQ ID NO: 108;
[0033] A primer pair for Aspergillus terreus, such as the primer pair shown in SEQ ID NO: 109 and SEQ ID NO: 110, and the primer pair shown in SEQ ID NO: 111 and SEQ ID NO: 112;
[0034] Primer pairs for Pneumocystis jirovecii include the primer pair shown as SEQ ID NO: 113 and SEQ ID NO: 114, the primer pair shown as SEQ ID NO: 115 and SEQ ID NO: 116, and the primer pair shown as SEQ ID NO: 117 and SEQ ID NO: 118.
[0035] In another aspect, the present invention relates to a kit for detecting respiratory pathogens, wherein the kit is used for detecting respiratory pathogens;
[0036] The respiratory pathogen is selected from at least one of Staphylococcus aureus, Mycobacterium tuberculosis complex, Streptococcus pneumoniae, Acinetobacter baumannii, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Mycoplasma pneumoniae, human adenovirus A, human adenovirus B, human adenovirus C, human adenovirus D, human adenovirus E, human adenovirus F, human adenovirus G, rhinovirus, new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, and Pneumocystis jiroveci;
[0037] The primer set of the present invention is selected according to the composition of the respiratory pathogens.
[0038] The present invention provides a primer set including 59 pairs of multiplex PCR primer pairs, which are specific primers designed for 27 pathogens, and each pathogen corresponds to at least one pair of primers. Those skilled in the art can select at least one pathogen from the 27 pathogens according to actual needs, and select the primer set of the present invention to form the above-mentioned kit for detecting respiratory pathogens.
[0039] The present invention uses 59 pairs of specific primers to achieve multiple targeted amplification of pathogen target regions, and uses a high-throughput sequencing platform to accurately identify pathogens. Therefore, the present invention further claims protection for a kit for detecting a targeted metagenomic genome of multiple respiratory pathogens, including the kit for detecting respiratory pathogens.
[0040] On the other hand, the present invention relates to a method for detecting multiple respiratory pathogens based on metagenomics, which is a non-disease diagnosis method, comprising: collecting a sample, and extracting the pathogen genome in the sample using a nucleic acid extraction kit;
[0041] Establishing a multiplex PCR reaction system, and using the kit for detecting respiratory pathogens according to claim 2 for amplification;
[0042] Purify the amplified product;
[0043] The libraries were mixed and sequenced;
[0044] Based on the sequencing results, respiratory pathogens in the sample are determined.
[0045] Furthermore, in the metagenomics-based detection method for multiple respiratory pathogens provided by the present invention, the nucleic acid extraction kit is a TIANMicrobe magnetic bead-based pathogenic microorganism DNA / RNA extraction kit.
[0046] Furthermore, in the metagenomics-based detection method for multiple respiratory pathogens provided by the present invention, in the mixed library sequencing, the size of the library fragments with different indexes is 500 bp pooling.
[0047] Furthermore, in the metagenomics-based detection method for multiple respiratory pathogens provided by the present invention, in the library mixed sequencing, the size of the NC fragment on the machine is 140 bp pooling.
[0048] Furthermore, in the metagenomics-based detection method for multiple respiratory pathogens provided by the present invention, in the library mixed sequencing, the concentration is 1.8 pM, the phix ratio is 30%, and the sequencing type is 101+10.
[0049] Compared with the prior art, the technical solution provided by the present invention has the following beneficial effects or advantages:
[0050] The present invention discloses a targeted metagenomic primer set and a kit for detecting a variety of respiratory pathogens, and uses targeted metagenomics to detect common infectious pathogens of the respiratory system, including common and rare key pathogenic microorganisms. The present invention achieves faster and more sensitive pathogen detection for key pathogens of the respiratory system, covering 3 G+, 6 G-, 1 mycoplasma, 7 DNA viruses, 5 RNA viruses, and 5 fungi. The present invention directly extracts nucleic acids from clinical samples, uses 59 pairs of specific primers to achieve multiple targeted amplification of pathogen target areas, uses a high-throughput sequencing platform, accurately identifies pathogens, and assists clinical rapid and accurate anti-infection treatment. At the same time, the pathogens included in this kit are relatively complete, the operation is relatively simple, and the detection is fast and accurate. The present invention is used for qualitative detection of key pathogens of the respiratory system, and only a small amount of clinical samples are required to complete the simultaneous detection of dozens or hundreds of pathogens at one time. The full process operation can be achieved in 20h~24h, and the data analysis system can be used to automatically output the test results. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0052] Figure 1 This is the detection step of the kit of the present invention.
[0053] Figure 2 The present invention compares the sensitivity of detection between the kit of the present invention and mNGS.
[0054] Figure 3 The present invention compares the specificity of detection between the kit of the present invention and mNGS.
[0055] Figure 4 Comparison of the positive predictive value of the test kit of the present invention and mNGS.
[0056] Figure 5 Comparison of the negative predictive values of the test kit of the present invention and mNGS.
[0057] Figure 6 This is a comparison of the detection accuracy of the kit of the present invention and mNGS. DETAILED DESCRIPTION
[0058] The technical solution of the present invention is described below in conjunction with embodiments; however, the present invention is not limited to the following embodiments.
[0059] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments, but the embodiments are not intended to limit the present invention.
[0060] The experimental methods and detection methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials are commercially available unless otherwise specified.
[0061] Example 1
[0062] This example is intended to illustrate the use of the targeted metagenomic primer set and kit provided by the present invention for detecting multiple respiratory pathogens.
[0063] When used to detect multiple respiratory pathogens, such as Figure 1 The following steps are shown:
[0064] (1) Collect samples and use a nucleic acid extraction kit to extract the pathogen genome in the samples;
[0065] (2) Establish a multiplex PCR reaction system, place primers and reaction components in a PCR instrument, add DNA templates extracted from the sample or reverse transcription products, and perform amplification;
[0066] (3) Purify the amplified product;
[0067] (4) The libraries are mixed and sequenced.
[0068] This embodiment is configured with a sample mixed with concentrations of Staphylococcus aureus, Mycobacterium tuberculosis complex, Streptococcus pneumoniae, Acinetobacter baumannii, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Mycoplasma pneumoniae, human adenovirus A, human adenovirus B, human adenovirus C, human adenovirus D, human adenovirus E, human adenovirus F, human adenovirus G, rhinovirus, new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, and Pneumocystis jiroveci, and 40 μL primer mix (Shanghai Biotechnology Co., Ltd., SEQ ID NO: 1~118, etc.) can be detected, and the minimum detection limit is 5 ng / μL.
[0069] Example 2
[0070] This example provides the detection of multiple respiratory pathogens in clinical samples.
[0071] (1) Collect patient samples and extract nucleic acid: Collect throat swabs, sputum or bronchoalveolar lavage fluid samples from patients, and use the TIANMicrobe magnetic bead-based pathogenic microorganism DNA / RNA extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., catalog number #NG550) to directly extract nucleic acid from the samples.
[0072] (2) One round of amplification:
[0073] PCR amplification was performed using Multiplex PCR Assay Kit Ver.2 (Bao-Ri Yi Biotechnology (Beijing) Co., Ltd., catalog number #RR062).
[0074] Configure the reaction system according to the table below:
[0075]
[0076] Use a pipette to draw 40 μL of primer mix (Shanghai Bioengineering Co., Ltd., SEQID NO: 1~118, etc.) into new 0.2 mL PCR tubes. Draw 50 μL of mineral oil (Sigma, catalog #M5310) and add it to the above tubes, then start adding samples. Put 10 μL of sample in. Run the instrument, heat cover at 105℃, reaction conditions: 94℃ 1min; 94℃ 30s, 63℃ 90s, 72℃ 10s, 26 cycles; 72℃ 1 min; Hold 10℃ ∞. After the end, place the PCR tube in a -20℃ refrigerator for about 2 minutes, then take it out and centrifuge it instantly.
[0077] (3) Fragment screening:
[0078] Pipette 25 μL of the amplified product into a new PCR tube, add 50 μL XP magnetic beads (Beckman Coulter, catalog number #A63882), place on the magnetic rack for 5 min, and discard the supernatant. Add 200 μL 80% ethanol, and after 30 seconds, discard the liquid. Add 200 μL 80% ethanol again, and after 30 seconds, discard the liquid, add 26 μL elution buffer, incubate at room temperature for 2 minutes, place on the magnetic rack for 2 minutes, and transfer 23 μL of the elution buffer to a new PCR tube for the next experiment.
[0079] (4) Second round of amplification:
[0080] Take 23 μL of the above round of purified liquid, add 25 μL 2×HiFi Amplification Mix (Tiangen Biochemical Technology (Beijing) Co., Ltd., Catalog No. #NG219), 2 μL Index primer Mix (Sangon Biotechnology (Shanghai) Co., Ltd.), and the total volume is 50 μL for PCR amplification. The hot cover is set to 105℃, and the reaction conditions are as follows:
[0081]
[0082] (5) Library purification:
[0083] Add 50 μL RNase-Free Water and 65 μL XP magnetic beads to the reaction tube, incubate at room temperature for 5 min, place on the magnetic rack for 5 min, and discard the supernatant. Add 200 μL 80% ethanol, and after 30 seconds, discard the 80% ethanol. Add 200 μL 80% ethanol again, and after 30 seconds, discard the 80% ethanol, add 30 μL elution buffer, incubate at room temperature for 2 min, place on the magnetic rack for 3 min, and transfer 27 μL of the elution buffer to a new PCR tube for the next experiment.
[0084] (6) Library mixing on the machine:
[0085] Libraries with different indexes were pooled according to the average fragment size of 500 bp, and NC was pooled according to the average fragment size of 140 bp. The concentration was 1.8 pM (according to the concentration measured after pooling), the phix ratio was 30%, and the sequencing type was 101+10.
[0086] The kit of the present invention (this embodiment) and the currently widely used metagenomic sequencing (mNGS) in clinical practice were used as comparative examples to test the standard samples of bronchoalveolar lavage fluid commonly used for testing patients with lower respiratory tract infection. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were analyzed. The results are shown in Tables 1 and Figures 2 to 6 shown.
[0087] The sensitivity calculation formula is: ;
[0088] The specificity calculation formula is: ;
[0089] The PPV calculation formula is: ;
[0090] The NPV calculation formula is: ;
[0091] The accuracy calculation formula is: ×100%.
[0092] Table 1 Comparison of detection sensitivity, specificity, PPV, NPV and accuracy
[0093]
[0094] As shown in Table 1 and Figures 2 to 6 As shown, the primer set and kit of the present invention can detect common pathogens of the respiratory system, including G+, G-, mycoplasma, viruses, fungi and other microbial species. Its sensitivity, specificity, PPV, NPV and accuracy are comparable to those of mNGS. As can be seen from the embodiments, only a small amount of clinical samples are needed to complete the simultaneous detection of dozens of pathogens at one time, and there will be no interference with the results, with good sensitivity, specificity, PPV, NPV and accuracy. The full process operation can be achieved in 20~24h, and the test results can be automatically output with the data analysis system.
[0095] As described above, the present invention can be well implemented. The above embodiments are only descriptions of the preferred implementation modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various changes and improvements made to the technical solutions of the present invention by ordinary technicians in this field should fall within the protection scope determined by the present invention.
Claims
1. A primer set, characterized in that: It consists of the following primer pairs: Primer pairs for Staphylococcus aureus, such as the primer pair shown in SEQ ID NO: 1 and SEQ ID NO: 2, the primer pair shown in SEQ ID NO: 3 and SEQ ID NO: 4, and the primer pair shown in SEQ ID NO: 5 and SEQ ID NO: 6; A primer pair for Mycobacterium tuberculosis complex, such as the primer pair shown in SEQ ID NO: 7 and SEQ ID NO: 8, and the primer pair shown in SEQ ID NO: 9 and SEQ ID NO: 10; A primer pair for Streptococcus pneumoniae, such as the primer pair shown in SEQ ID NO: 11 and SEQ ID NO: 12, the primer pair shown in SEQ ID NO: 13 and SEQ ID NO: 14, and the primer pair shown in SEQ ID NO: 15 and SEQ ID NO: 16; Primer pairs for Acinetobacter baumannii, such as the primer pair shown in SEQ ID NO: 17 and SEQ ID NO: 18, the primer pair shown in SEQ ID NO: 19 and SEQ ID NO: 20, and the primer pair shown in SEQ ID NO: 21 and SEQ ID NO: 22; A primer pair for Escherichia coli, such as the primer pair shown in SEQ ID NO: 23 and SEQ ID NO: 24, the primer pair shown in SEQ ID NO: 25 and SEQ ID NO: 26, and the primer pair shown in SEQ ID NO: 27 and SEQ ID NO: 28; A primer pair for Haemophilus influenzae, such as the primer pair shown in SEQ ID NO: 29 and SEQ ID NO: 30, the primer pair shown in SEQ ID NO: 31 and SEQ ID NO: 32, and the primer pair shown in SEQ ID NO: 33 and SEQ ID NO: 34; A primer pair for Klebsiella pneumoniae, such as the primer pair shown in SEQ ID NO: 35 and SEQ ID NO: 36, the primer pair shown in SEQ ID NO: 37 and SEQ ID NO: 38, and the primer pair shown in SEQ ID NO: 39 and SEQ ID NO: 40; A primer pair for Pseudomonas aeruginosa, such as the primer pair shown in SEQ ID NO: 41 and SEQ ID NO: 42, the primer pair shown in SEQ ID NO: 43 and SEQ ID NO: 44, and the primer pair shown in SEQ ID NO: 45 and SEQ ID NO: 46; A primer pair for Stenotrophomonas maltophilia, such as the primer pair shown in SEQ ID NO: 47 and SEQ ID NO: 48, the primer pair shown in SEQ ID NO: 49 and SEQ ID NO: 50, and the primer pair shown in SEQ ID NO: 51 and SEQ ID NO: 52; A primer pair for Mycoplasma pneumoniae, such as the primer pair shown in SEQ ID NO: 53 and SEQ ID NO: 54, the primer pair shown in SEQ ID NO: 55 and SEQ ID NO: 56, and the primer pair shown in SEQ ID NO: 57 and SEQ ID NO: 58; A primer pair for human adenovirus A, such as the primer pair shown in SEQ ID NO: 59 and SEQ ID NO: 60, and the primer pair shown in SEQ ID NO: 61 and SEQ ID NO: 62; A primer pair for human adenovirus B, such as the primer pair shown in SEQ ID NO: 63 and SEQ ID NO: 64, and the primer pair shown in SEQ ID NO: 65 and SEQ ID NO: 66; A primer pair for human adenovirus C, such as the primer pair shown in SEQ ID NO: 67 and SEQ ID NO: 68, and the primer pair shown in SEQ ID NO: 69 and SEQ ID NO: 70; A primer pair for human adenovirus D, such as the primer pair shown in SEQ ID NO: 71 and SEQ ID NO: 72, and the primer pair shown in SEQ ID NO: 73 and SEQ ID NO: 74; A primer pair for human adenovirus E, such as the primer pair shown in SEQ ID NO: 75 and SEQ ID NO: 76, and the primer pair shown in SEQ ID NO: 77 and SEQ ID NO: 78; A primer pair for human adenovirus F, such as the primer pair shown in SEQ ID NO: 79 and SEQ ID NO: 80, and the primer pair shown in SEQ ID NO: 81 and SEQ ID NO: 82; A primer pair for human adenovirus G, such as the primer pair shown in SEQ ID NO: 83 and SEQ ID NO: 84, and the primer pair shown in SEQ ID NO: 85 and SEQ ID NO: 86; A primer pair for rhinovirus, such as the primer pair shown in SEQ ID NO: 87 and SEQ ID NO: 88; A primer pair for the novel coronavirus, such as the primer pair shown in SEQ ID NO: 89 and SEQ ID NO: 90; A primer pair for influenza A virus, such as the primer pair shown in SEQ ID NO: 91 and SEQ ID NO: 92; A primer pair for influenza B virus, such as the primer pair shown in SEQ ID NO: 93 and SEQ ID NO: 94; A primer pair for respiratory syncytial virus, such as the primer pair shown in SEQ ID NO: 95 and SEQ ID NO: 96; A primer pair for Aspergillus flavus, such as the primer pair shown in SEQ ID NO: 97 and SEQ ID NO: 98, and the primer pair shown in SEQ ID NO: 99 and SEQ ID NO: 100; A primer pair for Aspergillus fumigatus, such as the primer pair shown in SEQ ID NO: 101 and SEQ ID NO: 102, and the primer pair shown in SEQ ID NO: 103 and SEQ ID NO: 104; A primer pair for Aspergillus niger, such as the primer pair shown in SEQ ID NO: 105 and SEQ ID NO: 106, and the primer pair shown in SEQ ID NO: 107 and SEQ ID NO: 108; A primer pair for Aspergillus terreus, such as the primer pair shown in SEQ ID NO: 109 and SEQ ID NO: 110, and the primer pair shown in SEQ ID NO: 111 and SEQ ID NO: 112; Primer pairs for Pneumocystis jirovecii include the primer pair shown as SEQ ID NO: 113 and SEQ ID NO: 114, the primer pair shown as SEQ ID NO: 115 and SEQ ID NO: 116, and the primer pair shown as SEQ ID NO: 117 and SEQ ID NO:
118.
2. A kit for detecting respiratory pathogens, characterized in that: The kit is used to detect respiratory pathogens; The respiratory pathogen is selected from at least one of Staphylococcus aureus, Mycobacterium tuberculosis complex, Streptococcus pneumoniae, Acinetobacter baumannii, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Mycoplasma pneumoniae, human adenovirus A, human adenovirus B, human adenovirus C, human adenovirus D, human adenovirus E, human adenovirus F, human adenovirus G, rhinovirus, new coronavirus, influenza A virus, influenza B virus, respiratory syncytial virus, Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus, and Pneumocystis jiroveci; The primer set of claim 1 is selected according to the composition of the respiratory pathogens.
3. A kit for detecting targeted metagenomes of multiple respiratory pathogens, characterized in that: A kit for detecting respiratory pathogens according to claim 2.
4. A method for detecting multiple respiratory pathogens based on metagenomics, which is a non-disease diagnostic method, characterized in that: include: Collect samples and use a nucleic acid extraction kit to extract the pathogen genome in the samples; Establishing a multiplex PCR reaction system, and using the kit for detecting respiratory pathogens according to claim 2 for amplification; Purify the amplified product; The libraries were mixed and sequenced; Based on the sequencing results, respiratory pathogens in the sample are determined.
5. The method for detecting multiple respiratory pathogens based on metagenomics according to claim 4, characterized in that: The nucleic acid extraction kit is a TIANMicrobe magnetic bead method pathogenic microorganism DNA / RNA extraction kit.
6. The method for detecting multiple respiratory pathogens based on metagenomics according to claim 4, characterized in that: In the library mixed sequencing, the fragment size of libraries with different indexes is 500 bp pooling.
7. The method for detecting multiple respiratory pathogens based on metagenomics according to claim 4, characterized in that: In the library mixed sequencing, the size of the NC fragment on the machine is 140 bp pooling.
8. The method for detecting multiple respiratory pathogens based on metagenomics according to claim 4, characterized in that: In the library mixed sequencing, the concentration was 1.8 pM, the phix ratio was 30%, and the sequencing type was 101+10.
Citation Information
Patent Citations
Method and kit for simultaneously detecting multiple pathogen genes
CN115948607A
Primer group, kit and detection method for detecting pathogens
CN111269995A
Kit and method for simultaneously detecting multiple pathogenic microorganisms tNGS
CN117757962A
